The Drug Enforcement Administration (DEA) is amending its regulations, in concert with the Department of Health and Human Services (HHS), to expand the circumstances under which individual practitioners are authorized to prescribe schedule III-V narcotic drugs or combinations of such drugs that have been approved for use in continuous medical treatment (also referred to as maintenance) or withdrawal management treatment (also referred to as detoxification)-- via a telemedicine encounter, including an audio-only telemedicine encounter.
US Federal Register - DEA Telehealth Rules · March 01, 2023
Expansion of Induction of Buprenorphine via Telemedicine Encounter
DEA expands authorization for practitioners to prescribe schedule III-V narcotic drugs for maintenance and withdrawal management via telemedicine, including audio-only encounters.
Published by US Federal Register - DEA Telehealth Rules. HealthSignal links to the original document; the summary above is extracted from the source text.